Title |
Phase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 years
|
---|---|
Published in |
Hematology Transfusion and Cell Therapy, January 2013
|
DOI | 10.5581/1516-8484.20130113 |
Pubmed ID | |
Authors |
Talita Stessuk, Milton Artur Ruiz, Oswaldo Tadeu Greco, Aldemir Bilaqui, Maria José de Oliveira Ribeiro-Paes, João Tadeu Ribeiro-Paes |
Abstract |
Chronic obstructive pulmonary disease is a major inflammatory disease of the airways and an enormous therapeutic challenge. Within the spectrum of chronic obstructive pulmonary disease, pulmonary emphysema is characterized by the destruction of the alveolar walls with an increase in the air spaces distal to the terminal bronchioles but without significant pulmonary fibrosis. Therapeutic options are limited and palliative since they are unable to promote morphological and functional regeneration of the alveolar tissue. In this context, new therapeutic approaches, such as cell therapy with adult stem cells, are being evaluated. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 33% |
Indonesia | 1 | 11% |
United Kingdom | 1 | 11% |
Korea, Republic of | 1 | 11% |
Unknown | 3 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 67% |
Practitioners (doctors, other healthcare professionals) | 3 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 3% |
Unknown | 62 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 13 | 20% |
Researcher | 9 | 14% |
Student > Doctoral Student | 8 | 13% |
Student > Master | 4 | 6% |
Professor | 2 | 3% |
Other | 9 | 14% |
Unknown | 19 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 27% |
Biochemistry, Genetics and Molecular Biology | 9 | 14% |
Agricultural and Biological Sciences | 5 | 8% |
Nursing and Health Professions | 3 | 5% |
Engineering | 3 | 5% |
Other | 7 | 11% |
Unknown | 20 | 31% |